Bulk Pharmaceutical API Sources for AZSTARYS

Bulk Pharmaceutical API Sources for AZSTARYS

Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical		2023-05-9C01243

AZSTARYS Bulk Active Pharmaceutical Ingredient (API) Sourcing Analysis

Last updated: February 19, 2026

This report identifies key bulk active pharmaceutical ingredient (API) sources for AZSTARYS, a prescription medication for Attention Deficit Hyperactivity Disorder (ADHD). The analysis focuses on patent landscape, active ingredient composition, and potential API manufacturers.

What is AZSTARYS?

AZSTARYS (serdexmethylphenidate and dexmethylphenidate) is a once-daily oral medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in individuals aged six years and older [1]. The product is developed by KemPharm and marketed by Jazz Pharmaceuticals [2].

Drug Composition

AZSTARYS combines two active ingredients:

• Serdexmethylphenidate: A prodrug that is hydrolyzed in the body to release dexmethylphenidate [3].
• Dexmethylphenidate: The active enantiomer of methylphenidate, a central nervous system stimulant [4].

The combination provides a dual-release mechanism, with serdexmethylphenidate offering a delayed release profile and dexmethylphenidate providing immediate release [5]. This formulation aims to offer sustained symptom control throughout the day.

Patent Landscape Analysis

The patent landscape surrounding AZSTARYS is a critical factor for API sourcing and market entry for potential generic manufacturers. Key patents relate to the composition of matter, formulation, and methods of use.

Composition of Matter and Formulation Patents

The primary patent covering the composition of matter for serdexmethylphenidate and its pharmaceutical formulations is U.S. Patent No. 8,790,672 [3, 6]. This patent, filed on May 23, 2011, and granted on July 29, 2014, has a statutory expiration date of May 23, 2031 [6].

Additional patents related to AZSTARYS formulations and methods of use may extend market exclusivity. For instance, U.S. Patent No. 9,446,054, titled "Prodrugs of D-threo-methylphenidate," also relates to serdexmethylphenidate and its therapeutic applications [7]. This patent has a statutory expiration date of April 5, 2027 [7].

KemPharm has also pursued patents covering specific aspects of the AZSTARYS formulation, such as delayed-release mechanisms and combinations of active ingredients. These patents, when identified and analyzed, could present further barriers or opportunities for generic development.

Patent Litigation and Exclusivity Periods

The expiration dates of key patents are essential for determining the timeline for potential generic competition. While statutory expiration dates provide a baseline, patent term extensions (PTE) granted by the USPTO for regulatory delays and potential patent challenges through inter partes review (IPR) or litigation can alter these timelines [8].

As of current reporting, specific details on patent litigation or PTEs for AZSTARYS patents are not publicly detailed in a manner that would definitively alter the projected exclusivity periods beyond the statutory expiration dates. However, prospective API manufacturers must conduct thorough due diligence on all relevant patents and potential legal challenges.

Bulk API Sourcing Considerations

Sourcing bulk active pharmaceutical ingredients (APIs) for AZSTARYS requires a focus on manufacturers capable of producing both serdexmethylphenidate and dexmethylphenidate to the required quality and regulatory standards.

Dexmethylphenidate API Sourcing

Dexmethylphenidate is the active enantiomer of methylphenidate. Several API manufacturers globally produce dexmethylphenidate, as it is an established API used in other ADHD medications like Focalin and Focalin XR [9].

Potential Dexmethylphenidate API Manufacturers:

• Dr. Reddy's Laboratories: A global pharmaceutical company with significant API manufacturing capabilities [10].
• Sun Pharmaceutical Industries Ltd.: A major Indian pharmaceutical company with a broad API portfolio [11].
• Lupin Ltd.: Another prominent Indian pharmaceutical firm known for its API production [12].
• Mallinckrodt Pharmaceuticals: Historically a significant producer of controlled substance APIs, including methylphenidate derivatives [13].
• ANI Pharmaceuticals, Inc.: Engaged in the development, manufacturing, and marketing of various pharmaceutical products, including APIs [14].

These manufacturers have experience with controlled substances and the complex synthesis required for chiral drugs like dexmethylphenidate. Due diligence should include assessing their current Good Manufacturing Practice (cGMP) compliance, regulatory filings (e.g., Drug Master Files - DMFs), and capacity for producing the required quantities.

Serdexmethylphenidate API Sourcing

Serdexmethylphenidate is a prodrug developed by KemPharm. As it is a proprietary molecule central to AZSTARYS, its primary production is likely controlled by KemPharm or its contracted manufacturing partners. The synthesis of serdexmethylphenidate involves more complex chemical steps than dexmethylphenidate, as it is a derivative designed to be hydrolyzed in vivo [3].

Sourcing Strategy for Serdexmethylphenidate:

Given the proprietary nature of serdexmethylphenidate, direct sourcing of bulk API from third-party manufacturers is likely limited until patent protections expire or licensing agreements are established.

1. KemPharm or Licensed Partners: The most direct route would be through KemPharm itself or its authorized contract manufacturing organizations (CMOs). This would involve engaging in licensing discussions or supply agreements.
2. Post-Patent Expiry: Following the expiration of key patents (e.g., U.S. Patent No. 8,790,672 in 2031), generic API manufacturers may develop their own synthetic routes and begin producing serdexmethylphenidate. This would require significant investment in process development and validation.
3. CMO Development: Companies specializing in complex API synthesis and prodrug development could be engaged to develop a non-infringing synthetic route for serdexmethylphenidate, pending patent expiry or licensing.

Identifying specific CMOs with expertise in prodrug synthesis and controlled substance manufacturing is crucial. These entities often operate under strict confidentiality agreements and require extensive qualification processes.

Regulatory and Quality Control Requirements

Manufacturing APIs for a controlled substance medication like AZSTARYS involves stringent regulatory oversight and quality control measures.

Controlled Substance Regulations

Both serdexmethylphenidate and dexmethylphenidate are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration (DEA) [15]. API manufacturers must:

• Obtain necessary DEA registrations and permits for handling, manufacturing, and distributing Schedule IV substances [16].
• Adhere to strict security protocols to prevent diversion.
• Maintain meticulous records of production, inventory, and distribution.
• Comply with quota requirements for controlled substances set by the DEA [16].

cGMP Compliance

All API manufacturing facilities must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory authorities like the FDA. This includes:

• Robust quality management systems.
• Validated manufacturing processes.
• Thorough testing of raw materials, in-process materials, and finished APIs.
• Stability testing to ensure API integrity over its shelf life.
• Strict change control procedures.
• Well-maintained facilities and equipment.

Drug Master Files (DMFs)

API manufacturers typically file Drug Master Files (DMFs) with regulatory agencies like the FDA. A DMF contains detailed information about the manufacturing process, facility, and quality controls for an API. Pharmaceutical companies seeking to use an API can reference the DMF in their drug product applications, which expedites the regulatory review process. API sourcing requires ensuring that a complete and approvable DMF is available or can be provided.

Market Dynamics and Future Outlook

The market for ADHD medications is substantial and continues to grow. AZSTARYS, with its novel dual-release mechanism, positions itself as a significant player.

Generic Competition Timeline

The primary driver for bulk API sourcing from third parties will be the emergence of generic versions of AZSTARYS. This is directly tied to the expiration of key patents. The earliest significant patent expiration impacting the core composition of matter for serdexmethylphenidate is May 23, 2031 [6].

• Pre-Patent Expiry: During the patent-protected period, API sourcing will likely be limited to KemPharm or its designated partners. Generic manufacturers may engage in development activities, including process R&D and DMF preparation, in anticipation of patent expiry.
• Post-Patent Expiry: Upon patent expiry, a surge in demand for both dexmethylphenidate and serdexmethylphenidate APIs is expected from multiple generic drug manufacturers. This will create opportunities for established API producers and specialized CMOs.

Competition for Dexmethylphenidate API

The market for dexmethylphenidate API is already established due to its use in other approved ADHD medications. Manufacturers with existing FDA-approved DMFs and established production lines for dexmethylphenidate are well-positioned to supply generic AZSTARYS products. Competition in this segment is likely to be price-driven and based on supply chain reliability and cGMP compliance.

Challenges for Serdexmethylphenidate API

The development of a generic serdexmethylphenidate API will be more challenging due to its proprietary nature and complex synthesis. Companies that can demonstrate a non-infringing synthetic route and successfully navigate the regulatory approval process will have a competitive advantage. This may involve significant investment in R&D and process innovation.

Key Takeaways

• AZSTARYS comprises serdexmethylphenidate and dexmethylphenidate, both classified as Schedule IV controlled substances.
• Key patents for AZSTARYS, notably U.S. Patent No. 8,790,672 for serdexmethylphenidate, expire in 2031, indicating potential generic entry thereafter.
• Dexmethylphenidate API is available from multiple established global manufacturers with prior experience in controlled substances.
• Serdexmethylphenidate API sourcing is currently limited to KemPharm or its authorized partners due to proprietary control and patent protection. Generic production is anticipated post-patent expiry.
• API manufacturers must demonstrate strict adherence to cGMP and DEA regulations for controlled substances, including maintaining approvable DMFs.
• The market for dexmethylphenidate API is competitive; serdexmethylphenidate API will present a greater challenge and opportunity for specialized API developers post-patent expiry.

Frequently Asked Questions

1. What is the earliest likely date for generic AZSTARYS API production to become widely available? The earliest significant patent protection for the core composition of matter of serdexmethylphenidate, as covered by U.S. Patent No. 8,790,672, expires in May 2031. Generic API production would typically commence around this period, contingent on successful development and regulatory filings.

2. Are there any known shortages of dexmethylphenidate API in the current market? While the broader methylphenidate market has experienced occasional supply chain challenges, specific shortages of dexmethylphenidate API for established products are not widely reported as of the current analysis. However, any API manufacturer must conduct real-time market surveillance.

3. What are the primary regulatory hurdles for a new API manufacturer seeking to produce serdexmethylphenidate API for the U.S. market? Key hurdles include developing a non-infringing synthetic process, securing DEA registration and quotas for a Schedule IV controlled substance, establishing robust cGMP-compliant manufacturing, and obtaining FDA approval for a DMF or as part of an Abbreviated New Drug Application (ANDA).

4. Can existing methylphenidate API manufacturers easily transition to producing dexmethylphenidate API? Manufacturers experienced with methylphenidate may have a foundational understanding of its chemistry. However, producing dexmethylphenidate, the specific enantiomer, requires validated chiral separation or asymmetric synthesis processes, and specific DEA registration for dexmethylphenidate.

5. What is the typical timeframe for developing and validating a novel synthetic route for a complex API like serdexmethylphenidate? The development and validation of a novel synthetic route for a complex API, especially a controlled substance prodrug, can take 2-5 years. This period encompasses process research and development, analytical method development, pilot scale-up, and extensive validation studies to meet regulatory requirements.

Citations

[1] FDA. (n.d.). FDA approves new drug for ADHD. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-adhd [2] KemPharm, Inc. (2021, March 10). KemPharm Announces FDA Approval of AZSTARYS (serdexmethylphenidate and dexmethylphenidate) Capsules. Business Wire. [3] U.S. Patent No. 8,790,672 (July 29, 2014). Prodrugs of D-threo-methylphenidate. [4] National Institute on Drug Abuse. (2020, April 28). Methylphenidate. NIDA. Retrieved from https://www.drugabuse.gov/publications/drugfacts/methylphenidate [5] Jazz Pharmaceuticals. (n.d.). AZSTARYS. Retrieved from https://www.jazzpharma.com/our-products/azstarys/ [6] U.S. Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. Retrieved from https://patft.uspto.gov/ (Search for Patent No. 8,790,672) [7] U.S. Patent No. 9,446,054 (April 5, 2016). Prodrugs of D-threo-methylphenidate. [8] U.S. Food and Drug Administration. (n.d.). Hatch-Waxman Act: Patent Term Restoration. FDA. Retrieved from https://www.fda.gov/drugs/patent-certification-and-patent-infringement-litigation/hatch-waxman-act-patent-term-restoration [9] U.S. Food and Drug Administration. (n.d.). DailyMed. Retrieved from https://dailymed.nlm.nih.gov/ (Search for Focalin, Focalin XR) [10] Dr. Reddy's Laboratories. (n.d.). API Services. Retrieved from https://www.drreddys.com/ [11] Sun Pharmaceutical Industries Ltd. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.sunpharma.com/ [12] Lupin Ltd. (n.d.). API Business. Retrieved from https://www.lupin.com/ [13] Mallinckrodt Pharmaceuticals. (n.d.). API Manufacturing. Retrieved from https://www.mallinckrodt.com/ [14] ANI Pharmaceuticals, Inc. (n.d.). Contract Manufacturing. Retrieved from [https://www.ani.com/](https://www.ani> Pharmaceuticals, Inc. (n.d.). Contract Manufacturing. Retrieved from https://www.ani.com/ [15] U.S. Drug Enforcement Administration. (n.d.). Controlled Substance Schedules. DEA. Retrieved from https://www.dea.gov/drug-scheduling [16] U.S. Drug Enforcement Administration. (n.d.). Registration for Manufacturers. DEA. Retrieved from https://www.deadiversion.usdoj.gov/reg_files/